Skip to main content
52°
Sunny
Site search
Search
Menu
Search
Subscribe
Open user controls
Log In Using Your Account
Log In
Don't have an account?
Sign Up Today
My Account
Dashboard
Profile
Saved items
Logout
Home
Contact Us
Subscribe
News
East Greenwich Pendulum
Kent County Daily Times
Narragansett Times
NK Standard-Times
Sports
Features
Special Sections
Local Guide
Local Events
Markets & Stocks
Weather
League of Women Voters SRI
League of Women Voters WS
Classifieds
Place ad
Legal Notices
Place Kent Legal
Place SRI Class Legal
Search SRI Legals
Search Kent Legals
Obituaries
Subscribe
E-Edition
Community Choice
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by Stoke Therapeutics, Inc.
< Previous
1
2
Next >
Stoke Therapeutics Reports Third Quarter Financial Results and Provides Business Updates
November 05, 2024
From
Stoke Therapeutics, Inc.
Via
Business Wire
Tickers
STOK
Stoke Therapeutics Presents Zorevunersen Data Showing Substantial Reductions in Seizures and Improvements in Multiple Measures of Cognition and Behavior That Support the Potential for Disease Modification in Dravet Syndrome
September 10, 2024
From
Stoke Therapeutics, Inc.
Via
Business Wire
Tickers
STOK
Stoke Therapeutics Appoints Eric Olson, MS, MBA as Chief Business Officer
September 04, 2024
From
Stoke Therapeutics, Inc.
Via
Business Wire
Tickers
STOK
Stoke Therapeutics to Present at Upcoming Investor Conferences in September
September 03, 2024
From
Stoke Therapeutics, Inc.
Via
Business Wire
Tickers
STOK
Stoke Therapeutics to Present Encore Data at the 15th European Epilepsy Congress that Demonstrate the Potential for Zorevunersen to be the First Disease-Modifying Medicine for the Treatment of Dravet Syndrome
September 03, 2024
From
Stoke Therapeutics, Inc.
Via
Business Wire
Tickers
STOK
Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
August 16, 2024
From
Stoke Therapeutics, Inc.
Via
Business Wire
Tickers
STOK
Stoke Therapeutics Reports Second Quarter Financial Results and Provides Business Updates
August 07, 2024
From
Stoke Therapeutics, Inc.
Via
Business Wire
Tickers
STOK
Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
July 16, 2024
From
Stoke Therapeutics, Inc.
Via
Business Wire
Tickers
STOK
Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
June 18, 2024
From
Stoke Therapeutics, Inc.
Via
Business Wire
Tickers
STOK
Stoke Therapeutics to Present at Upcoming Investor Conferences in June
June 03, 2024
From
Stoke Therapeutics, Inc.
Via
Business Wire
Tickers
STOK
Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
May 17, 2024
From
Stoke Therapeutics, Inc.
Via
Business Wire
Tickers
STOK
Stoke Therapeutics Reports First Quarter Financial Results and Provides Business Updates
May 06, 2024
From
Stoke Therapeutics, Inc.
Via
Business Wire
Tickers
STOK
Stoke Therapeutics Appoints Thomas Leggett as Chief Financial Officer
April 29, 2024
From
Stoke Therapeutics, Inc.
Via
Business Wire
Tickers
STOK
Stoke Therapeutics Appoints Jason Hoitt as Chief Commercial Officer
April 17, 2024
From
Stoke Therapeutics, Inc.
Via
Business Wire
Tickers
STOK
Stoke Therapeutics to Present at the 23rd Annual Needham Virtual Healthcare Conference
April 04, 2024
From
Stoke Therapeutics, Inc.
Via
Business Wire
Tickers
STOK
Stoke Therapeutics Announces Pricing of Upsized $125 Million Public Offering
March 27, 2024
From
Stoke Therapeutics, Inc.
Via
Business Wire
Tickers
STOK
Stoke Therapeutics Announces Proposed Public Offering
March 26, 2024
From
Stoke Therapeutics, Inc.
Via
Business Wire
Tickers
STOK
Stoke Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results
March 25, 2024
From
Stoke Therapeutics, Inc.
Via
Business Wire
Tickers
STOK
Stoke Therapeutics Announces Landmark New Data That Support the Potential for STK-001 to be the First Disease-Modifying Medicine for the Treatment of Patients with Dravet Syndrome
March 25, 2024
From
Stoke Therapeutics, Inc.
Via
Business Wire
Tickers
STOK
Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
January 17, 2024
From
Stoke Therapeutics, Inc.
Via
Business Wire
Tickers
STOK
Stoke Therapeutics Highlights Strategic Priorities and Anticipated Milestones for 2024
January 08, 2024
From
Stoke Therapeutics, Inc.
Via
Business Wire
Tickers
STOK
Stoke Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference
January 04, 2024
From
Stoke Therapeutics, Inc.
Via
Business Wire
Tickers
STOK
Stoke Therapeutics Presents Data From Multiple Studies of Children and Adolescents With Dravet Syndrome at the American Epilepsy Society (AES) 2023 Annual Meeting
December 01, 2023
From
Stoke Therapeutics, Inc.
Via
Business Wire
Tickers
STOK
Stoke Therapeutics to Present Data from the Company’s Dravet Syndrome Clinical Program at the American Epilepsy Society 2023 Annual Meeting
November 21, 2023
From
Stoke Therapeutics, Inc.
Via
Business Wire
Tickers
STOK
Stoke Therapeutics Reports Third Quarter Financial Results and Provides Business Updates
November 07, 2023
From
Stoke Therapeutics, Inc.
Via
Business Wire
Tickers
STOK
Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
October 17, 2023
From
Stoke Therapeutics, Inc.
Via
Business Wire
Tickers
STOK
Stoke Therapeutics to Participate in the 2023 Cantor Global Healthcare Conference
September 21, 2023
From
Stoke Therapeutics, Inc.
Via
Business Wire
Tickers
STOK
Stoke Therapeutics Appoints Ian Smith to its Board of Directors
September 20, 2023
From
Stoke Therapeutics, Inc.
Via
Business Wire
Tickers
STOK
Stoke Therapeutics Presents Data Related to the Ongoing Clinical Development of STK-001 for the Treatment of Dravet Syndrome at the 35th International Epilepsy Congress
September 05, 2023
From
Stoke Therapeutics, Inc.
Via
Business Wire
Tickers
STOK
Stoke Therapeutics Reports Second Quarter Financial Results and Provides Business Updates
August 07, 2023
From
Stoke Therapeutics, Inc.
Via
Business Wire
Tickers
STOK
< Previous
1
2
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.